Home › Triple-Negative Breast Cancer › Georgia › Atlanta
Triple-Negative Breast Cancer clinical trials in Atlanta, GA
20 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- Emory University, Atlanta
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Emory Winship Cancer Institute, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
RecruitingPhase 2
- Emory University (Data Collection Only), Atlanta
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RecruitingPhase 2
- Emory University, Atlanta
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
RecruitingPhase 1/2
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Northside Hospital, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- Winship Cancer Institute, Emory University, Atlanta
Study of XB010 in Subjects With Solid Tumors
RecruitingPhase 1
- Winship Cancer Institute, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Winship Cancer Institute / Emory University, Atlanta
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
RecruitingPhase 2
- Emory University Hospital, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
RecruitingObservational studyHealthy volunteers welcome
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- Winship Cancer Institute of Emory University, Atlanta
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
RecruitingPhase 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
RecruitingPhase 1
- Emory University, Winship Cancer Institute, Atlanta
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RecruitingPhase 1/2
- Winship Cancer Institute - Emory University, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
RecruitingPhase 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- and 1 more
A Beta-only IL-2 ImmunoTherapY Study
RecruitingPhase 1/2
- Emory - Winship Cancer Institute, Atlanta
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
- Grand Rapids, MI15 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Multiple Myeloma42 studies
- Breast Cancer41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia31 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Metastatic Cancer28 studies
- Major Depressive Disorder25 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.